Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)

Trial Identifier: D1699R00036
Sponsor: AstraZeneca
NCTID:: NCT05465213
Start Date: November 2022
Primary Completion Date: December 2023
Study Completion Date: December 2023
Condition: Congestive Heart Failure

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Portugal, NA Porto, NA, Portugal, NA
Portugal, NA Porto, NA, Portugal, NA
Portugal, NA Porto, NA, Portugal, NA
Portugal, NA Porto, NA, Portugal, NA
Portugal, NA Porto, NA, Portugal, NA
Portugal, NA Porto, NA, Portugal, NA
Portugal, NA Porto, NA, Portugal, NA
Portugal, NA Porto, NA, Portugal, NA